ArticleInternational journal of surgery case reports2025
The use of Pretiva™ negative pressure therapy provides benefits in the management of hard-to-heal chronic wounds: A case series.
Article in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and importanceChronic wounds pose a major global health challenge, often leading to prolonged disability, increased healthcare costs, and significant patient suffering. Conventional therapies frequently fail to achieve complete healing in complex cases, highlighting the need for innovative, cost-effective solutions. Portable negative pressure wound therapy devices (NPWT), offer new opportunities to enhance wound healing, particularly in emerging healthcare systems. CASE PRESENTATION: We report two cases of patients with hard-to-heal lower limb wounds. The first case involved a 48-year-old male with a chronic venous ulcer and repeated soft tissue infections. The second case involved a 52-year-old female with a chronic post-traumatic wound unresponsive to multiple surgical interventions. Both patients demonstrated significant clinical improvement following the application of Pretiva™ NPWT, including tissue regeneration, reduction of wound area, absence of exudate and odor, and decreased risk of limb loss. CLINICAL DISCUSSION: These cases illustrate how NPWT effectively reactivated healing in wounds that had stagnated under conventional care. The therapy's mechanisms enhancing microcirculation, reducing edema, and promoting granulation tissue formation, translated into rapid, clinically meaningful outcomes. The portability and ease of use of NPWT also support its feasibility in outpatient and resource-limited settings, addressing key gaps in chronic wound management in emerging countries.
conclusionThis case series illustrates the potential therapeutic value of Pretiva™ NPWT in the management of hard-to-heal chronic wounds. Its observed effectiveness and practical feasibility in outpatient and resource-constrained settings suggest it may be a valuable option in similar clinical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.